CO2022016323A2 - Derivados de triazina que tienen actividad inhibidora de la replicación del virus y composición farmacéutica que constituye el mismo - Google Patents

Derivados de triazina que tienen actividad inhibidora de la replicación del virus y composición farmacéutica que constituye el mismo

Info

Publication number
CO2022016323A2
CO2022016323A2 CONC2022/0016323A CO2022016323A CO2022016323A2 CO 2022016323 A2 CO2022016323 A2 CO 2022016323A2 CO 2022016323 A CO2022016323 A CO 2022016323A CO 2022016323 A2 CO2022016323 A2 CO 2022016323A2
Authority
CO
Colombia
Prior art keywords
pharmaceutical composition
same
inhibitory activity
virus replication
composition constituting
Prior art date
Application number
CONC2022/0016323A
Other languages
English (en)
Original Assignee
Shionogi & Co
Univ Hokkaido Nat Univ Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shionogi & Co, Univ Hokkaido Nat Univ Corp filed Critical Shionogi & Co
Publication of CO2022016323A2 publication Critical patent/CO2022016323A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
    • C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
    • C07D251/12—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D251/26—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hetero atoms directly attached to ring carbon atoms
    • C07D251/40—Nitrogen atoms
    • C07D251/42—One nitrogen atom
    • C07D251/46—One nitrogen atom with oxygen or sulfur atoms attached to the two other ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invención proporciona un compuesto que exhibe un efecto inhibidor de la proteasa 3CL del coronavirus y sus sales farmacéuticamente aceptables, y una composición farmacéutica que contiene el mismo. Además, se proporcionan cristales que son útiles como una sustancia farmacológica y una composición farmacéutica que contiene los mismos. El compuesto representado por la fórmula (1) o sus sales farmacéuticamente aceptables.
CONC2022/0016323A 2021-04-14 2022-11-15 Derivados de triazina que tienen actividad inhibidora de la replicación del virus y composición farmacéutica que constituye el mismo CO2022016323A2 (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
JP2021068672 2021-04-14
JP2021105802 2021-06-25
JP2021153819 2021-09-22
PCT/JP2022/006496 WO2022138988A1 (ja) 2021-04-14 2022-02-17 ウイルス増殖阻害作用を有するトリアジン誘導体およびそれらを含有する医薬組成物

Publications (1)

Publication Number Publication Date
CO2022016323A2 true CO2022016323A2 (es) 2023-02-16

Family

ID=82159864

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2022/0016323A CO2022016323A2 (es) 2021-04-14 2022-11-15 Derivados de triazina que tienen actividad inhibidora de la replicación del virus y composición farmacéutica que constituye el mismo

Country Status (14)

Country Link
US (2) US20230128162A1 (es)
EP (2) EP4122926A4 (es)
JP (2) JP7530596B2 (es)
KR (2) KR20230159812A (es)
CN (6) CN117820248A (es)
AU (1) AU2022204775B2 (es)
CA (1) CA3195272C (es)
CL (1) CL2023003041A1 (es)
CO (1) CO2022016323A2 (es)
IL (1) IL298794B2 (es)
MX (1) MX2022014458A (es)
TW (1) TWI815396B (es)
WO (2) WO2022138988A1 (es)
ZA (1) ZA202212526B (es)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2022014458A (es) * 2021-04-14 2023-02-27 Shionogi & Co Derivados de triazina que tienen actividad inhibidora de la replicacion del virus y composicion farmaceutica que constituye el mismo.
WO2023033098A1 (ja) * 2021-09-03 2023-03-09 塩野義製薬株式会社 ウイルス増殖阻害活性を有する二環性含窒素複素環誘導体およびそれらを含有する医薬組成物
CN116782904A (zh) * 2021-09-28 2023-09-19 盐野义制药株式会社 含有三嗪衍生物的医药组合物
WO2023054292A1 (ja) * 2021-09-28 2023-04-06 塩野義製薬株式会社 トリアジン誘導体を含有する医薬組成物
JP7236065B1 (ja) * 2021-09-28 2023-03-09 塩野義製薬株式会社 トリアジン誘導体を含有する医薬組成物
JP7261529B1 (ja) 2021-11-24 2023-04-20 塩野義製薬株式会社 ウイルス増殖阻害作用を有するトリアジン誘導体の製造方法
AU2022333823A1 (en) 2021-11-24 2024-05-02 Shionogi & Co., Ltd. Preparation for oral administration containing triazine derivative
JPWO2023095860A1 (es) * 2021-11-26 2023-06-01
KR20240137021A (ko) * 2022-01-19 2024-09-19 시오노기 앤드 컴파니, 리미티드 신형 코로나바이러스 감염증 치료용 의약
WO2023165459A1 (en) * 2022-03-01 2023-09-07 Fochon Biosciences , Ltd. Compounds as sars-cov-2 inhibitors
US11655240B1 (en) 2022-05-10 2023-05-23 Beijing Grand Johamu Pharmaceutical Company, Ltd. Crystal form of compound and fumaric acid, pharmaceutical composition and method for treating coronavirus-induced diseases
CN114805314B (zh) * 2022-04-20 2023-12-15 杭州国瑞生物科技有限公司 一种恩赛特韦的合成方法
CN117122601A (zh) * 2022-05-27 2023-11-28 北京远大九和药业有限公司 包含化合物与富马酸的结晶形式的药物组合物及其制备方法和用途
WO2023227118A1 (zh) * 2022-05-27 2023-11-30 广州国家实验室 3c样蛋白酶抑制剂
CN117159556A (zh) * 2022-05-27 2023-12-05 北京远大九和药业有限公司 一种药物组合物及其制备方法和用途
WO2023227117A1 (zh) * 2022-05-27 2023-11-30 广州国家实验室 3c样蛋白酶抑制剂
CN117126137A (zh) * 2022-05-27 2023-11-28 广州国家实验室 3c样蛋白酶抑制剂
CN115260167A (zh) * 2022-08-01 2022-11-01 陕西盘龙药业集团股份有限公司 一种3-四唑基甲基-1,3,5-三嗪-2,4-二酮类化合物及其制备方法和应用
US20240025885A1 (en) * 2022-07-08 2024-01-25 Ascletis BioScience Co., Ltd Triazine derivatives and methods of use thereof
CN116496266A (zh) * 2022-07-08 2023-07-28 歌礼生物科技（杭州）有限公司 三嗪衍生物
CN114989048B (zh) * 2022-07-19 2023-05-23 郑州大学 环丁-1-烯胺类化合物及其制备方法和在抗ⅱ型登革病毒药物中的应用
CN114933594A (zh) * 2022-07-20 2022-08-23 北京科翔中升医药科技有限公司 一种氟代三嗪类化合物、药物组合物及用途
CN115109042B (zh) * 2022-08-30 2023-05-26 北京科翔中升医药科技有限公司 三嗪类化合物或其可药用的盐、药物组合物和用途
CN115504968B (zh) * 2022-11-21 2023-04-18 歌礼生物科技（杭州）有限公司 三嗪衍生物
CN115819407A (zh) * 2022-12-13 2023-03-21 浙江乐普药业股份有限公司 一种Ensitrelvir类似物及其制备方法和抗新冠用途
CN115785080B (zh) * 2022-12-16 2024-10-11 陕西盘龙药业集团股份有限公司 一种尿嘧啶母核类化合物及其制备方法和应用
CN115991700A (zh) * 2023-01-20 2023-04-21 厦门蔚扬药业有限公司 一种含硒的三嗪衍生物及其制备方法和用途
CN116621817B (zh) * 2023-07-20 2023-09-29 爱斯特（成都）生物制药股份有限公司 一种富马酸恩赛特韦的晶型及其制备方法、药物组合物和用途

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2631625B1 (fr) * 1988-05-17 1992-10-16 Synthelabo Derives de phenyl-6 piperazinylalkyl-3 1h,3h-pyrimidinedione-2,4, leur preparation et leur application en therapeutique
JP3032844B2 (ja) * 1990-02-15 2000-04-17 武田薬品工業株式会社 ピリミジンジオン誘導体
EP1255738B1 (en) * 2000-01-25 2012-03-07 Neurocrine Biosciences, Inc. Gonadotropin-releasing hormone receptor antagonists and methods relating thereto
MXPA06004789A (es) * 2003-10-31 2006-07-03 Cv Therapeutics Inc Antagonistas del receptor de adenosina a2b.
CN1926128A (zh) * 2004-03-15 2007-03-07 武田药品工业株式会社 二肽基肽酶抑制剂
AU2004318013B8 (en) * 2004-03-15 2011-10-06 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
CA2602576A1 (en) * 2005-03-24 2006-10-05 Janssen Pharmaceutica N.V. Prokineticin 1 receptor antagonists
JP5122462B2 (ja) * 2005-09-16 2013-01-16 武田薬品工業株式会社 ジペプチジルペプチダーゼ阻害剤
CN100502868C (zh) * 2005-11-18 2009-06-24 北京大学 非肽类sars冠状病毒3cl蛋白酶抑制剂及其用途
CN101495464B (zh) * 2005-12-29 2014-03-05 詹森药业有限公司 激肽原1受体拮抗剂
EP1999108A1 (en) * 2006-03-28 2008-12-10 Takeda Pharmaceutical Company Limited Preparation of (r)-3-aminopiperidine dihydrochloride
DK2170848T3 (en) * 2007-06-27 2015-01-05 Astrazeneca Ab Pyrazinonderivater and their use to treat lung diseases
US8324380B2 (en) * 2007-10-30 2012-12-04 Janssen Pharmaceutica Nv Amino-heteroaryl-containing prokineticin 1 receptor antagonists
CA2752269C (en) * 2009-02-13 2016-08-30 Hiroyuki Kai Novel triazine derivative and pharmaceutical composition comprising the same
US20110319418A1 (en) * 2010-06-28 2011-12-29 Flores Christopher M Prokineticin 1 receptor antagonists for the treatment of pain
CA2803545A1 (en) * 2010-06-28 2012-01-12 Janssen Pharmaceutica Nv Prokineticin 1 receptor antagonists for the treatment of pain
WO2012009258A2 (en) 2010-07-13 2012-01-19 Edward Roberts Peptidomimetic galanin receptor modulators
WO2012020749A1 (ja) * 2010-08-10 2012-02-16 塩野義製薬株式会社 トリアジン誘導体およびそれを含有する鎮痛作用を有する医薬組成物
JP6075621B2 (ja) 2010-08-10 2017-02-08 塩野義製薬株式会社 新規複素環誘導体およびそれらを含有する医薬組成物
CN102807568B (zh) * 2011-05-31 2015-11-25 正大天晴药业集团股份有限公司 噻二唑衍生物类dpp-iv抑制剂
CN103159665B (zh) * 2011-12-09 2017-01-25 天津市国际生物医药联合研究院 对sars冠状病毒主蛋白酶具有抑制作用的靛红‑5‑酰胺类抑制剂
TW201331188A (zh) * 2011-12-15 2013-08-01 Shionogi & Co 經取代之三□衍生物及含有其之醫藥組成物
WO2013118855A1 (ja) 2012-02-09 2013-08-15 塩野義製薬株式会社 複素環および炭素環誘導体
TWI637949B (zh) * 2013-06-14 2018-10-11 塩野義製藥股份有限公司 胺基三衍生物及含有其等之醫藥組合物
KR102222569B1 (ko) * 2013-10-25 2021-03-05 샹하이 헨그루이 파마수티컬 컴퍼니 리미티드 피리딘의 케톤 유도체의 제조 방법 및 제약 용도
CN104109147B (zh) * 2014-06-21 2016-10-05 安徽省逸欣铭医药科技有限公司 羟基脒基苯类衍生物及其制备方法和医药用途
US10183949B2 (en) * 2014-08-29 2019-01-22 The University Of Tokyo Pyrimidinone derivative having autotaxin-inhibitory activity
JP7116356B2 (ja) * 2017-11-28 2022-08-10 日産化学株式会社 トリアジン－２，４－ジオン誘導体及びその製造方法
EP3953361A1 (en) 2020-04-05 2022-02-16 Pfizer Inc. Compounds and methods for the treatment of covid-19
CN112516122A (zh) * 2020-04-21 2021-03-19 洪楠方 苏拉明在制备预防或治疗冠状病毒相关疾病药物中的用途
WO2022035911A2 (en) * 2020-08-11 2022-02-17 Tutela Pharmaceuticals, Inc. Methods of treating coronavirus infections by co-administering an fkbp ligand and an antiviral agent
US11351149B2 (en) 2020-09-03 2022-06-07 Pfizer Inc. Nitrile-containing antiviral compounds
JPWO2022158528A1 (es) * 2021-01-20 2022-07-28
WO2022212314A1 (en) * 2021-03-29 2022-10-06 Shireen Nature Company For General Trading, Ltd. Willow extract and its use in treating coronavirus infection, inflammation, and associated medical conditions
MX2022014458A (es) * 2021-04-14 2023-02-27 Shionogi & Co Derivados de triazina que tienen actividad inhibidora de la replicacion del virus y composicion farmaceutica que constituye el mismo.
CN113801097B (zh) 2021-09-27 2022-11-22 成都施贝康生物医药科技有限公司 二氢嘧啶类化合物、其制备方法及用途
CN113620888B (zh) 2021-09-27 2023-06-06 成都施贝康生物医药科技有限公司 二氢嘧啶类化合物及其制备方法和应用
CN113666914B (zh) 2021-09-27 2022-06-07 成都施贝康生物医药科技有限公司 二氢嘧啶类化合物及其制备方法和用途
CN113773300B (zh) 2021-09-27 2022-10-11 成都施贝康生物医药科技有限公司 磺酰胺类化合物、其制备方法及用途
CN113735838B (zh) 2021-09-27 2022-07-08 成都施贝康生物医药科技有限公司 二氢嘧啶类化合物、其制备方法及用途
CN116782904A (zh) * 2021-09-28 2023-09-19 盐野义制药株式会社 含有三嗪衍生物的医药组合物
WO2023054292A1 (ja) * 2021-09-28 2023-04-06 塩野義製薬株式会社 トリアジン誘導体を含有する医薬組成物
AU2022333823A1 (en) * 2021-11-24 2024-05-02 Shionogi & Co., Ltd. Preparation for oral administration containing triazine derivative
KR20240137021A (ko) * 2022-01-19 2024-09-19 시오노기 앤드 컴파니, 리미티드 신형 코로나바이러스 감염증 치료용 의약
CN114591304B (zh) * 2022-05-10 2022-07-12 北京远大九和药业有限公司 一种化合物的结晶形式及其制备方法和用途

Also Published As

Publication number Publication date
CN115850249A (zh) 2023-03-28
CA3195272A1 (en) 2022-06-30
US20230212154A1 (en) 2023-07-06
JP7530596B2 (ja) 2024-08-08
EP4122926A1 (en) 2023-01-25
TWI815396B (zh) 2023-09-11
JPWO2022138988A1 (es) 2022-06-30
CN115038696A (zh) 2022-09-09
TW202302571A (zh) 2023-01-16
ZA202212526B (en) 2023-05-31
AU2022204775A1 (en) 2022-12-08
CN115073431A (zh) 2022-09-20
CN115073431B (zh) 2023-09-05
CL2023003041A1 (es) 2024-03-15
WO2022138988A1 (ja) 2022-06-30
IL298794A (en) 2023-02-01
KR20230159812A (ko) 2023-11-22
KR20220142999A (ko) 2022-10-24
AU2022204775B2 (en) 2023-03-30
IL298794B1 (en) 2024-02-01
CA3195272C (en) 2024-02-13
US11814368B2 (en) 2023-11-14
IL298794B2 (en) 2024-06-01
CN116650498A (zh) 2023-08-29
EP4400502A2 (en) 2024-07-17
KR102494188B1 (ko) 2023-01-31
EP4122926A4 (en) 2023-08-30
JP7105430B1 (ja) 2022-07-25
US20230128162A1 (en) 2023-04-27
JPWO2022138987A1 (es) 2022-06-30
MX2022014458A (es) 2023-02-27
CN115850249B (zh) 2024-07-02
CN118359592A (zh) 2024-07-19
CN117820248A (zh) 2024-04-05
WO2022138987A1 (ja) 2022-06-30

Similar Documents

Publication Publication Date Title
CO2022016323A2 (es) Derivados de triazina que tienen actividad inhibidora de la replicación del virus y composición farmacéutica que constituye el mismo
DOP2022000183A (es) Derivados de biarilo como inhibidores de la interacción proteína-proteína de yap/taz-tead
DOP2022000124A (es) Derivados de pirazolilo útiles como agentes anticancerígenos
CL2020002578A1 (es) Benzofurano, benzopirrol, benzotiofeno sustituidos y otros inhibidores del complemento estructuralmente relacionados
AR058338A1 (es) Derivados de pirrol fusionado, composiciones farmaceuticas que los contienen y su uso en la preparacion de un medicamento para el tratamiento de enfermedades mediadas por la inhibicion de la quinasa.
UY35273A (es) Tiadiazol, análogos del mismo, y métodos para el tratamiento de condiciones relacionadas con defici encia de smn
CL2022000257A1 (es) Regímenes de dosificación para inhibidores orales del factor d del complemento
CL2021001396A1 (es) Derivados de panteteína y usos de los mismos
ES2376043T3 (es) Derivados de indazol para el tratamiento de enfermedades inducidas por hsp90.
AR079208A2 (es) Inhibidores de la actividad de proteina tirosina quinasa, composicion y uso de dichos inhibidores para la preparacion de un medicamento para tratar una enfermedad, trastorno o condicion oftalmica
CR20220553A (es) Pirrolopirimidinaminas como inhibidores del sistema del complemento
ES2980476T3 (es) Derivados de tienopiridina y composición farmacéutica que los contiene
CL2022000875A1 (es) Inhibidores del factor d del complemento para administración oral
CL2021001537A1 (es) Formas cristalinas y formas de sal de un inhibidor de cinasa
CL2018000529A1 (es) Compuestos heteroarilo y su uso como fármacos terapéuticos.
CL2019000768A1 (es) Compuestos de aza-indazol para usar en lesiones de tendones y/o ligamentos.
SV2016005313A (es) Derivados de carboxamida
CL2021002480A1 (es) Agonistas compuestos macrocíclicos como de sting
ECSP22036455A (es) Inhibidores del factor d del complemento para administraci?n oral
CO2022008616A2 (es) Composición farmacéutica oral que comprende compuesto de carbamato y método de preparación para la misma
AR114418A1 (es) Compuesto cíclico de metilactama y su utilización farmacéutica
CO2023015732A2 (es) Moduladores de trex1
UY38006A (es) Inhibidores de la quinasa mtor, composiciones farmacéuticas que los contienen, y al uso en terapia de tales compuestos y composiciones
AR070882A1 (es) 1, 3 -tiazoles sustituidos como inhibidores de mmp-2 y/o mmp-9.
UY38934A (es) Inhibidores de o-glucoproteína-2-acetamido-2-deoxi-3-d-glucopiranosidasa espirocíclica